Literature DB >> 16704699

Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden.

Gisela Kobelt1, Björn Jonsson, Anders Bergström, Enping Chen, Christina Lindén, Albert Alm.   

Abstract

PURPOSE: To investigate the effect of different levels of visual field defect in glaucoma on utilities and to test if utilities could be assessed using a general questionnaire such as the EQ-5D.
METHODS: A cross-sectional study in 199 patients with ocular hypertension or open-angle glaucoma grouped into 5 severity stages according to visual field defects was performed in 4 specialized ophthalmic centres. Descriptive analysis was performed for the sample and by stage, and the effect of vision loss on utility was investigated with multiple step-wise regression analysis.
RESULTS: The mean age of the sample was 70 and the mean MD in the worse eye was -13.1 dB (SD 10.2). Visual acuity (VA) was 0.63 and 0.87 in the worse and better eye, respectively, and the mean utility was 0.80 (SD 0.23). Utility decreased with increasing glaucomatous damage, ranging from 0.84 for mild disease to 0.72 for severe damage (MD -2.5 to -28.1), but the difference between the groups was not statistically significant when controlling for co-morbidity, except for the most severe stage (p < 0.01). In multiple regression analysis, visual field in the better eye was significantly correlated with utility, and there was an indirect correlation between visual field in the worse eye and utility: the effect of total VA on utility was significant, and MD in the worse eye was correlated with total VA.
CONCLUSIONS: Utility is strongly correlated with overall vision. Our results suggest a relationship between glaucomatous damage and utility, and patients with severe damage have a significantly lower utility. However, this should be further investigated in larger samples that include more patients with moderate-severe bilateral damage.

Entities:  

Mesh:

Year:  2006        PMID: 16704699     DOI: 10.1111/j.1600-0420.2005.00621.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  25 in total

1.  The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.

Authors:  Gary C Brown; Melissa M Brown; Heidi C Brown; Sylvia Kindermann; Sanjay Sharma
Journal:  Trans Am Ophthalmol Soc       Date:  2007

Review 2.  [Value-based medicine for glaucoma].

Authors:  C Hirneiss; A Kampik; A S Neubauer
Journal:  Ophthalmologe       Date:  2010-03       Impact factor: 1.059

3.  Estimating quality-adjusted life years from patient-reported visual functioning.

Authors:  C Browne; J Brazier; J Carlton; Y Alavi; M Jofre-Bonet
Journal:  Eye (Lond)       Date:  2012-07-06       Impact factor: 3.775

4.  [Health economical aspects of telemedical glaucoma monitoring].

Authors:  T Swierk; C Jürgens; R Grossjohann; S Flessa; F Tost
Journal:  Ophthalmologe       Date:  2011-04       Impact factor: 1.059

5.  Validity of EuroQOL-5D, time trade-off, and standard gamble for age-related macular degeneration in the Singapore population.

Authors:  K G Au Eong; E W Chan; N Luo; S H Wong; N W H Tan; T H Lim; A M Wagle
Journal:  Eye (Lond)       Date:  2012-01-06       Impact factor: 3.775

6.  [Measurement of glaucoma-specific functionality with the GQL-15 and correlation with parameters of visual function].

Authors:  C Hirneiss; M Vogel; A Kampik; A S Neubauer; M Kernt
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

7.  Comparative studies of RNFL thickness measured by OCT with global index of visual fields in patients with ocular hypertension and early open angle glaucoma.

Authors:  Sergios Taliantzis; Dimitris Papaconstantinou; Chrysanthi Koutsandrea; Michalis Moschos; Michalis Apostolopoulos; Gerasimos Georgopoulos
Journal:  Clin Ophthalmol       Date:  2009-06-29

8.  [Health-economic aspects of glaucoma screening].

Authors:  C Hirneiss; A Niedermaier; M Kernt; A Kampik; A S Neubauer
Journal:  Ophthalmologe       Date:  2010-02       Impact factor: 1.059

Review 9.  Quality of life in glaucoma and three other chronic diseases: a systematic literature review.

Authors:  Tim Mills; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

10.  The quality of life impact of peripheral versus central vision loss with a focus on glaucoma versus age-related macular degeneration.

Authors:  Keith Evans; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Clin Ophthalmol       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.